Resources from the same session
Second-line afatinib vs methotrexate (MTX) in patients (pts) with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC): subgroup/biomarker analysis of LUX-head and neck 1 (LUX-H&N1)
Presenter: Makoto Tahara
Session: Head and neck cancer
Invited discussant abstract 314O
Presenter: Fortunato Ciardiello
Session: Head and neck cancer
Resources:
Early or delayed use of TKI
Presenter: Makoto Tahara
Session: Head and neck cancer
Antitumor activity and safety of pembrolizumab in patients with PD-L1-positive nasopharyngeal carcinoma: Interim results from a phase 1b study
Presenter: Chiun Hsu
Session: Head and neck cancer